Winton Group’s Apogee Therapeutics APGE Stock Holding History

Winton Group’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,617	Closed	-$635K	–	722
2025 Q2	$635K	Buy	+14,617	New	+$556K	0.03%	541

Other funds holding APGE

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Winton Group's APGE Position: Q3 2025 in Review

Winton Group sold out of Apogee Therapeutics (APGE) in Q3 2025, closing a stake of 14,617 shares — an estimated $635K sold.

Winton Group first reported a position in APGE in Q2 2025 and held it in 1 quarter. The position peaked at $635K in Q2 2025. 174 funds tracked by Wall St. Rank hold APGE as of Q3 2025.

Winton Group reported no remaining Apogee Therapeutics position as of Q3 2025 after selling out during the quarter.
Winton Group sold 14,617 Apogee Therapeutics shares in Q3 2025, an estimated $635K.
Winton Group first reported a position in Apogee Therapeutics in Q2 2025 and held it in 1 quarter.
Winton Group's Apogee Therapeutics position peaked at $635K in Q2 2025.
174 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2025.

Based on Winton Group's 13F filing for Q3 2025, filed 13 Nov 2025.